WADA publishes laboratory guidelines

Today, the World Anti-Doping Agency (WADA) published the following WADA-accredited laboratory guidelines, which take effect immediately.

1. The Guideline for Conducting and Reporting Subcontracted Analysis and Further Analysis for Doping Control, version 2.0, dated June 2018 has been developed to ensure a harmonized approach in the analysis and reporting of samples, which are shipped to another laboratory for subcontracted analyses or for further analysis of long-term stored samples [as described in the International Standard for Laboratories (ISL)]. This Guideline also provides direction on several scenarios that may require that a sample be shipped between laboratories, including how to report the results into WADA’s Anti-Doping Administration and Management System (ADAMS).
2. The revised Guideline for TUE Enquiries by Accredited Laboratories, version 2.0, dated June 2018, which assists laboratories in reporting Presumptive Adverse Analytical Findings exclusively for the S.3. Beta-2 Agonists and S.9. Glucocorticoids drug classes; and, in enquiring with the relevant Testing Authority and/or Results Management Authority about the existence of an approved Therapeutic Use Exemption (TUE) before performing confirmation analyses.